# National Taiwan University Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-taiwan-university-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48.5 |
| Citations | 4,169,666 |
| City | Taipei |
| Country | TW |
| Description | National Taiwan University Hospital is a research organisation in Taipei, TW. OpenAlex records 52,030 works and 4,169,666 citations for it. 11,730 researchers list it as their most recent affiliation. |
| Homepage | http://www.ntuh.gov.tw/en/default_P.aspx |
| OpenAlex ID | https://openalex.org/I4210131804 |
| Region | Taiwan |
| Researchers | 11,730 |
| ROR ID | https://ror.org/03nteze27 |
| Type | healthcare |
| Works | 52,030 |

## University papers

Showing 12 of 139.

- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes](https://scholariq.org/papers/cancer-regression-and-autoimmunity-in-patients-after-clonal-repopulation-with/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update](https://scholariq.org/papers/asian-pacific-clinical-practice-guidelines-on-the-management-of-hepatitis-b-a/)
- [Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma](https://scholariq.org/papers/use-of-tumor-infiltrating-lymphocytes-and-interleukin-2-in-the-immunotherapy-of/)
- [Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy](https://scholariq.org/papers/durable-complete-responses-in-heavily-pretreated-patients-with-metastatic/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)](https://scholariq.org/papers/biomarker-analyses-and-final-overall-survival-results-from-a-phase-iii/)

## University researchers

- [James Chih‐Hsin Yang](https://scholariq.org/researchers/james-chih-hsin-yang/)
- [Chong‐Jen Yu](https://scholariq.org/researchers/chong-jen-yu/)
- [Jin‐Yuan Shih](https://scholariq.org/researchers/jin-yuan-shih/)
- [Lian‐Yu Lin](https://scholariq.org/researchers/lian-yu-lin/)
- [Li‐Kai Tsai](https://scholariq.org/researchers/li-kai-tsai/)
- [Chao‐Chi Ho](https://scholariq.org/researchers/chao-chi-ho/)
- [Yung‐Tsu Cho](https://scholariq.org/researchers/yung-tsu-cho/)
- [Tom C. Chan](https://scholariq.org/researchers/tom-c-chan/)
- [Pin‐Fei Wei](https://scholariq.org/researchers/pin-fei-wei/)
- [W.-Y. Liao](https://scholariq.org/researchers/w-y-liao/)
- [K.-Y. Chen](https://scholariq.org/researchers/k-y-chen/)
- [T.-H. Tsai](https://scholariq.org/researchers/t-h-tsai/)
- [C.-Y. Yang](https://scholariq.org/researchers/c-y-yang/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cardiac Arrest and Resuscitation](https://scholariq.org/topics/cardiac-arrest-and-resuscitation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.